rs193922239 — FBN1

FBN1 Gly2627Arg — A Crack in the Connective Tissue Scaffold

Every arterial wall, every lens zonule, every ligament that holds your skeleton together depends on a microscopic scaffolding called the microfibril¹¹ microfibril
a rope-like structure in the extracellular matrix assembled from fibrillin-1 molecules end-to-end, providing elasticity and tensile strength to connective tissue throughout the body. Fibrillin-1 is encoded by FBN1 — a 66-exon gene on chromosome 15 producing a 2,871-amino-acid glycoprotein studded with 47 epidermal growth factor-like (EGF-like) domains. Forty-three of these domains are calcium-binding (cbEGF), and calcium ions are essential to their structural rigidity. A single amino acid substitution in any one of these domains can be enough to compromise the entire fibrillin polymer.

The p.Gly2627Arg substitution — coded by two different nucleotide changes at the same genomic position (NC_000015.10:g.48415708C>G or C>T, both producing the same coding-strand change c.7879G>C or c.7879G>A on the minus-strand FBN1 transcript) — replaces a small, flexible glycine with a bulky, positively charged arginine at position 2627 of fibrillin-1. This position sits within a cbEGF-like domain in the C-terminal half of the protein. ClinVar classifies this variant as Pathogenic/Likely Pathogenic with multiple independent submissions²² Pathogenic/Likely Pathogenic with multiple independent submissions
ClinVar VCV000372606, criteria provided, multiple submitters, no conflicts, including a 2025 Pathogenic classification from Labcorp Genetics/Invitae. The variant is essentially absent from population databases (not detected in ALFA across

187,000 alleles), consistent with its role as a rare, high-penetrance disease allele.

The Mechanism

Glycine residues in EGF-like domains serve as structural pivots³³ Glycine residues in EGF-like domains serve as structural pivots
glycine's side chain is a single hydrogen atom, making it uniquely suited for tight turns and compact folds that other amino acids cannot achieve. Substituting glycine with arginine introduces a large, charged side chain that distorts the calcium-binding loop. When calcium fails to bind correctly, the cbEGF domain cannot fold into its normal rigid rod-like conformation. This locally misfolded domain then disrupts the folding of adjacent domains through a propagation effect, ultimately destabilizing the entire fibrillin-1 monomer. Abnormal fibrillin-1 impairs microfibril polymerization through a dominant-negative mechanism⁴⁴ dominant-negative mechanism
the defective monomer interferes with the assembly of normal monomers into functional microfibrils, so even one mutant copy disrupts the whole network, explaining why a single heterozygous copy is sufficient to cause disease.

Beyond structural weakness, impaired fibrillin-1 microfibrils fail to sequester transforming growth factor-beta (TGF-β) in the extracellular matrix. Excessive free TGF-β signaling drives aortic smooth muscle cell dysfunction, progressive aortic wall stiffening, and the aneurysmal dilatation that is the leading cause of premature death in Marfan syndrome.

The Evidence

Dietz et al. (Genomics, 1993)⁵⁵ Dietz et al. (Genomics, 1993) established that all known FBN1 missense mutations causing classic Marfan syndrome at that time fell at residues with calcium-binding significance in EGF-like domains — the same structural domain affected by Gly2627Arg. The clinical phenotype associated with cbEGF missense mutations is consistently severe, including cardiovascular, ocular, and skeletal manifestations.

The most important clinical outcome data come from the French Marfan cohort followed by Milleron et al. (JACC, 2020)⁶⁶ Milleron et al. (JACC, 2020): 954 patients with FBN1 pathogenic variants followed over 8,594 patient-years showed that type A aortic dissection occurred at only 0.4 events per 1,000 patient-years when the maximal aortic diameter remained below 50 mm with guideline-directed treatment (beta-blockers, exercise restriction). The key message: risk is manageable when diagnosed early and monitored diligently.

On the treatment side, Brooke et al. (N Engl J Med, 2008)⁷⁷ Brooke et al. (N Engl J Med, 2008) demonstrated that the angiotensin receptor blocker losartan reduced aortic root dilation rate from 3.54 mm/yr to 0.46 mm/yr in 18 pediatric Marfan patients — an approximately 87% reduction — by blocking TGF-β pathway activation. This finding underpins the current guideline recommendation to add an ARB if aortic progression rate exceeds 5 mm/year or root diameter exceeds 40 mm in children.

Practical Actions

FBN1 pathogenic variant carriers require structured, lifelong cardiac surveillance. Annual transthoracic echocardiography is the standard; cardiac MRI can be added for improved accuracy, especially at the aortic sinuses and ascending aorta. Medical therapy with a beta-blocker or ARB (commonly losartan) reduces hemodynamic stress on the aortic wall and should be initiated at diagnosis or upon confirming progressive dilation. Prophylactic aortic root surgery is recommended when the root approaches 5.0 cm in adults or progresses rapidly regardless of absolute diameter.

Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin, moxifloxacin) are contraindicated for this genotype — they inhibit lysyl oxidase, the enzyme responsible for cross-linking collagen and elastin, and have been linked to aortic aneurysm rupture and dissection in connective tissue disorder patients. Decongestants and vasoconstrictors (including nasal decongestants, triptans for migraine) should be used only under medical supervision given their effects on aortic wall stress.

Annual ophthalmologic examination is also indicated: approximately 60% of Marfan patients develop ectopia lentis (lens dislocation) and are at elevated risk for retinal detachment and glaucoma.

Interactions

The dominant-negative mechanism of FBN1 missense mutations means that second-hit variants in fibrillin-1 or in related extracellular matrix genes are unlikely (two pathogenic FBN1 alleles causes a severe neonatal Marfan phenotype that is not typically compatible with adulthood). However, modifier effects in TGF-β pathway genes (TGFBR1, TGFBR2, SMAD2, SMAD3) have been described in related connective tissue disorders — Loeys-Dietz syndrome — and may influence phenotypic severity in FBN1 carriers. Carriers who also have variants in ACTA2 or MYH11 (smooth muscle genes associated with familial thoracic aortic aneurysm) may warrant more aggressive surveillance thresholds, though formal compound genotype data for this specific FBN1 variant are not published.